SSE Ticker: 600249

Liuzhou Liangmianzhen Co., Ltd.

两面针

Authorized Representative: 林钻煌

Board: Main A

Industry Classification: Manufacturing

[The most complete] Comprehensive comparison of listed companies in the proprietary Chinese medicine industry in North China in 2021__中国医疗

Post date September 15, 2021 — 13:46 Post Lock

Announcement of Liuzhou Liangmianzhen Co., Ltd. on convening the 2021 semi-annual performance briefing

Post date September 11, 2021 — 10:00 Post Lock

Old brands are not living well? Take a look at these listed companies, some of which have revenues of over 100 billion in half a year-Finance-Finance

Post date September 8, 2021 — 17:44 Post Lock

Listed cosmetics companies show half-year performance, many companies have both increased revenue and net profit

Post date September 6, 2021 — 12:25 Post Lock

Chinese medicinal materials have soared. Why should 6 listed companies pay attention to the concept of Chinese medicine when they have deployed upstream resources? The reasons are as follows: 1. I recently went to a pharmacy to buy medicines and found that the prices of several different commonly used medicines have increased, and the price increases have been relatively large. 2. Recently in the news… Snowball

Post date September 4, 2021 — 20:19 Post Lock

Listed company securities investment perspective 9 companies with investment amount exceeding tens of billions

Post date August 30, 2021 — 06:25 Post Lock

Listed company securities investment perspective 9 companies investment amount exceeds 10 billion-Stock Channel-Hexun.com

Post date August 30, 2021 — 04:50 Post Lock

[The most complete] Comprehensive comparison of listed companies in the Chinese patent medicine industry in Northwest China in 2021 (with business layout summary, performance comparison, business planning, etc.)

Post date August 29, 2021 — 15:03 Post Lock

That's horrible! The market value is less than 4 billion to invest in this company, or the blood loss is more than 400 million, and the stock price of the investment target has been cut in half.

Post date August 28, 2021 — 07:50 Post Lock

That's horrible! The market value is less than 4 billion to invest in this company, or the blood loss is more than 400 million, and the stock price of the investment target has been cut in half.

Post date August 28, 2021 — 07:15 Post Lock

Interim report: 30 shares reduced loss and 1 share loss-340 million-CFi.CN 中财网

Post date August 26, 2021 — 08:06 Post Lock

Interim report: 30 shares reduced loss and 1 share loss-340 million-CFi.CN 中财网

Post date August 26, 2021 — 07:26 Post Lock

Liangmianzhen: The sales revenue of household toothpaste in the second quarter is 29,835,800 yuan

Post date August 25, 2021 — 18:48 Post Lock

China's first natural ingredients listed on Nasdaq, rose more than 60% in a week, there is still room for three times the upside-Business-Finance

Post date July 5, 2021 — 20:45 Post Lock